BioSpace News Archive

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401.

“The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations are continuing according to plan,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.

111, Inc. announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2019 ended December 31, 2019, before the open of U.S. markets on Thursday, March 12, 2020.

111, Inc. has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus public health crisis, through partnerships with some of China’s leading financial institutions to distribute medical services via apps to their extensive consumer bases.

Delta Dental released new findings from its Original Tooth Fairy Poll® that show a 30-cent increase in the Tooth Fairy’s average cash gift for a total of $4.03 per tooth.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the investigator-initiated expanded access protocol using its cryopreserved allogeneic cell therapy product candidate remestemcel-L for steroid-refractory chronic graft versus host disease (chronic GVHD) has resulted in clinically meaningful outcomes in all three treated patients, two children and one adult, within 28 days after two infusions.

i:X Platform’s Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds

Dyve Biosciences, a research and drug development company using proprietary science to create novel therapeutics, today announced it has enrolled its first patient in TARGETS, a Phase 2 clinical study of DYV-700, the company’s topically administered therapeutic being developed as a treatment for acute gout.

Bluestar Adisseo Company, a world leader in feed additives for animal nutrition, and the world’s leading alternative protein producer, Calysta, signed an agreement to establish a joint venture named Calysseo to develop FeedKind®, an innovative feed solution for aquaculture, and to provide exclusive supply for Asian markets.

DaVita Kidney Care recently announced Kenny Gardner as its new chief people officer (CPO)